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ABSTRACT 
Anxiety disorders are among most frequent mental disorders encountered by Clinicians. Untreated anxiety may result in increase 
health care utilization, morbidity, mortality and poorer quality of life. Individual with GAD, social phobias and panic disorder 
show less satisfaction with their quality of life. Basolateral amygdale has been implicated in anxiety generations. Mutations in Sk3 
(calcium channel) are suspected to be underlying cause of severe neurological disorder including anxiety.  Therapeutic effects of 
benzodiazepine are usually or often sustained over months or years, with the need for increased dosage in the treatment of GAD 
and panic disorders. Flurazepam is a hypnotic agent useful for the treatment of insomnia characterized by frequent nocturnal 
awakening and other insomnia symptoms such as trouble falling or staying sleep. It acts on BZ1 and BZ2 receptor sites. The 
mechanism of action of zopiclone is similar to benzodiazepines, but it wines more selectively to BZ1 receptor with similar effects 
on locomotor activity and on dopamine and serotonin turnover. Zopiclone although molecularly different from benzodiazepines, 
shares  an  almost  identical  pharmacological  profile  as  benzodiazepines  including  anxiolytic  properties.  The  present  study  is 
designed to assess two drugs of different classes that act through same receptor against control for their effects on some of the 
behavioral activities. Results indicated that zopiclone produced reduction in anxiety more than flurazepam.  
 
Key words: Anxiety, Benzodiazepines, GAD, hypnotic agent, insomnia 
 
1. INTRODUCTION 
Anxiety disorders are among most frequent mental disorders encountered by clinicians. Untreated anxiety may result 
in increase health care utilization, morbidity, mortality and poorer quality of life. Anxiety is of many types, attacks of 
anxiety that are accompanied by physiological manifestations and people with this disorders often undergoing medical 
evaluation for symptoms related to heart attacks or other medical conditions. Panic attacks may occur at any time even 
during sleep.  
When the body does not get enough rest required, the brain cannot think clearly, but tries to do it. In this 
process  patient  get  panic  and  anxiety  attacks.  Similarly,  when  patient  suffering  from  anxiety  disorder,  they  can 
experience difficulties in sleep patterns, which can lead to insomnia. Insomnia is a symptom, which is characterized 
by persistent difficulty in falling asleep. It is typically accompanied by functioning impairment when awake. All 
behavioral and environmental factors that precede sleep may interfere with sleep
1. Mind body therapy such as stimulus 
control therapy and cognitive behavioral therapy are particularly helpful. If sleep hygiene do not help, prescription 
may be an appropriate choice and the best medication is benzodiazepine that include flurazepam. Another class of 
sedative hypnotic medication includes the non benzodiazepine receptor agonists which include zolpidem, zaleplon and 
zopiclone. 
Benzodiazepines have been found useful in a remarkably wide and varied array of such clinical applications. 
Most traditional clinical use has been based on their anxiolytic, hypnotic, anticonvulsant and antispastic effects. Other 
possibly related effects demonstrated in clinical trials and practice includes antipanic, antidepressants, amnestic and 
anesthetic effects.  
Flurazepam  is  one  of  benzodiazapines,  which  has  several  different  effects  on  body,  including  relaxing 
muscles, reducing anxiety, causing sleepiness, stopping seizures and impairing short term memory. Benzodiazepines 
agonist and other agonist ligands at benzodiazepines site achieve their therapeutic effects by enhancing the action of 
the inhibitory neurotransmitter GABA (gamma amino butyric acid) at its receptor. The central GABA receptor, known 
as GABA A receptor, consist of  at least four subunits; three of these alpha, beta and gamma each contain three to six 
variants. Benzodiazepines binds at the interference of alpha and gamma subunits of GABAA receptor binding also 
requires that alpha subunit contains a histidine amino acid residue and hence Benzodiazepine show no affinity for 
GABA A receptor containing α 4 and α 6 subunits with arginine instead of histidine
2. 
Two GABA receptors have been identified anatomically and pharmacologically. These receptors are variably 
called type-I and type-II, Benzodiazepine-I and Benzodiazepine -II, or omega-I and omega –II are located out much of 
the central nervous system. The omega –I site has been associated with the alpha-I subunit, where as the omega –II 
site appear to be heterogeneous, located on receptors with α-2, α-3 and α-5 subunits. Most of the Benzodiazepines 
currently available for therapeutic use are consider being full agonists at the Benzodiazepine site. Benzodiazepine also 
functions as weak adenosine reuptake inhibitors, and the anticonvulsant, anxiolytic and muscle relaxant effects are 
mediated through GABAA action
3. When used to treat anxiety or sleep disorders flurazepam is usually given orally. 
Flurazepam produces a metabolite with very longer half life (140-250 hours), and is therefore only used for short term Pakistan Journal of Chemistry 2011 
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treatment of insomnia, and is considered to be hypnotic
4. Flurazepam which is mainly used for hypnosis, is oxidized 
by  hepatic  enzymes  to  three  active  metabolites,  Desalkylflurazepam,  hydroxymethylflurazepam  and 
flurazepamaldehyde have elimination half-lives ranging 30-100 hours. This may result in unwanted central nervous 
system depression. In most cases, changes in renal function do not have marked effect on the elimination of parent 
drugs. The most common side effects of flurazepam in routine clinical use are manifestations of excessive depression 
of the CNS, adverse effects on other physiological system are rare. Side effects include drowsiness, muscle weakness, 
light headedness, vertigo, heartburn, nausea, vomiting, ataxia, diplopia, blurring of vision, apathy, severe sedation, 
disorientation  and  coma.  There  have  also  been  rare  occurrence  of  leucopenia,  granulocytopenia,  sweating, 
hypotension, shortness of breath, purities, skin rash, dry mouth, euphoria, depression, slurred speech and paradoxical 
reactions e.g. Excitement, agitation, aggressive behavior and anxiety. The flurazepam with drawl syndrome has been 
described  by  many  authors.  The  syndrome  can  be  of  considerable  severity  and  have  similarities  to  abstinence 
syndromes  associated  with  alcohol,  opiates  and  barbiturates.  Muscle  cramps,  vomiting,  sweating  have  occurred 
following abrupt discontinuation of flurazepam. 
BZ1 receptors that occur in brain areas  are involved in sedation, where as BZ2 are highly concentrated in areas 
responsible for cognition, memory and psychomotor functioning. While benzodiazepines act selectively on two BZ 
receptors sub-type, newer such as zopiclone, zolpidem etc are more selective agents and have similar hypnotic activity 
but reduced CNS unwanted effects. The mechanism of action of zopiclone is similar to benzodiazepines, with similar 
effects on locomotor activity and on dopamine and serotonin turnover. Zopiclone although molecularly different from 
benzodiazepines, shares an almost similar pharmacological profile as benzodiazepines including anxiolytic properties. 
Its mechanism of action is via binding to the benzodiazepine site which in turn positively modulates benzodiazepine 
sensitive  GABAA  receptors  to  produce  zopiclone’s  pharmacological  properties.  Zopiclone  is  the  oldest  of  new 
compounds considered here, having been introduced in the late 1970s. Most controlled studies of zopiclone have 
compared the hypnotic effects of 7.5 mg dose with those of benzodiazepines hypnotic dose. In studies using subjective 
ratings,  zopiclone  was  equivalent  to  flurazepam  30  mg,  triazolam  0.25  mg  and  nitrazepam  5mg  on  most  or  all 
measures. Zopiclone is used for the treatment of short term insomnia. It is suitable in a dosage from 3.75 to7.5 mg for 
cases of insomnia that are not accompanied by anxiety. After oral administration, zopiclone is rapidly absorbed, with 
bioavailability of 80%. The plasma protein binding of zopiclone has been reported to be between 45-80%. It is widely 
and rapidly distributed to body tissues including the brain and other. It is partly metabolized in the liver in form of 
inactive N-demethylated derivative and an active N-oxide metabolite. Zopiclone is excreted in urine, saliva and breast 
milk.  The  pharmacokinetic  of  zopiclone  is  altered  by  aging  and  is  influenced  by  renal  and  hepatic  functions
5. 
Zopiclone is short to intermediate acting, with half life ranging from 3.5 to 6.5 hours and has no active metabolites. 
The mechanism of action of zopiclone is same as that of benzodiazepines with similar effects on locomotor activity 
and on dopamine and serotonin turn over. Zopiclone acts at the benzodiazepine binding site on α 1, 2, 3 & 5 GABAA 
containing receptors as full agonists causing an enhancement of the action of GABA to produce the therapeutic and 
adverse effect of zopiclone. Zopiclone and its active metabolite desmethylzopiclone also inhibit N-methyl-D-aspartate 
receptor  (NMDA)  and  nicotinic  acetylcholine  receptors  (nACHRs)  which  might  play  additive  role  in  addictive 
properties  of  these  drugs.  The  most common  side effects  are  taste  alteration  or dysgeusia (bitter  metallic taste). 
Palpitation may occur at day time following withdrawal from the drug after prolong use. It induces amnesia type 
memory impairments, impairments to driving skills with a resultant increased risk of road accidents. At the level of 
CNS, disruption of REM sleep, double vision, drowsiness, headache and fatigue is observed. Abrupt withdrawal 
particularly with prolonged and high doses can in severe cases causes seizures and delirium
6.  
 
2. PURPOSE OF STUDY 
Prescription medications such as  benzodiazepines that include flurazepam  may cause psychological and physical 
dependence because of non-selectivity to receptors site. Physical withdrawal symptoms may occur if the drug is 
tapered for long term use. The newer sedative and hypnotic drugs includes non  benzodiazepine, benzodiazepine 
receptor agonists, zopiclone are more selective for benzodiazepine receptor BZ1. These newer appear to have better 
safety profiles and fewer adverse effects than benzodiazepines; they are also associated with low risk of abuse and 
dependence than benzodiazepines, although dependence occur. The present study is designed to assess two drugs of 
different classes that act through same receptors against control for their effects on some behavioral activities. The 
permission for carrying out the research work was granted by department of Pharmacology, University of Karachi. 
 
3. EXPERIMENTAL 
The present study was conducted on 30 locally bred Swiss albino rats purchased from HEJ research institute of 
chemistry. All were male, divided into three groups each comprising of 10 rats, weighing between 150-200gm, housed 
in standard size poly propylene cages and maintained in reserve light and dark cycle of 12 hours each. Animals were 
fed on standard diet, water and libitum. Flurazepam HCl and zopiclone were used in the experiment against control 
animals which were treated with saline only. Dose of the drugs were calculated according to the body weight of 
animals, zopiclone 7.5 mg/60 kg and flurazepam 15mg/ kg. The tablets of both the drugs were crushed and powderedNajam et al, 2011 
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and were diluted with water, the suspension was then given to rats with feeding tubes in the morning. The drugs were 
administered for duration of 4 weeks as follows:  
 
No of animals  Control  Drug Treated 
10  Saline  - 
10  -  Zopiclone 
10  -  Flurazepam 
 
All the animals were weighed before starting the experiment and at the end of the study.  
The various experimental parameters monitored during the treatment were as follows: 
 
3.1 Gross behavior 
All the animals were observed for acute behavioral changes which include: grooming, straub’s phenomena, writhing, 
tremors,  twitches,  righting  reflex,  pinna  reflex,  corneal  reflex,  exopthalamus,  salivation,  lacrimation,  defecation, 
urination and motor activity etc. 
 
3.2 Open field activity 
Animals were kept in the center of the square area measuring 76x76 cms with walls of 72 cm in height and the 
changes in behavior were observed against control animals exactly after 30 minutes of oral administration, this was 
continuously repeated on alternate days and observed finally after 28 days. 
 
3.3 Cage crossing 
The activity of both control and treated animals was observed weekly by placing animals in cage and allow them to 
move freely and the number of crossings with all four paws was scored for 10 minutes and was observed finally after 
28 days. 
Animals were forced to swim in the water tank, as they are not habituated for swimming they tried to escape 
and struggle for it for 2-3 minutes then stop struggling and start swimming. The duration in which rats struggle, is 
called struggling time. 
 
3.4 Exploratory behavior 
To determine this activity each animal was kept in a square box having 16 equally spaced small holes called head dip 
apparatus. Rats because of inquisitive nature try to explore by dipping head in each hole several times, and tries to 
escape from these holes. According to the cut off time of 10 minutes, the number of times it dips its head is calculated 
and noted. 
 
3.5 Grip Test 
The animals are forced to hang on a wire or rod for a period of ten minutes and note the traction time for which the 
animals were hanged. The experiment was repeated on alternate days and finally on day 28. 
 
4. STATISTICAL ANALYSIS 
Results are presented as mean + standard error of the mean (S.E.M). Data on the effects of zopiclone, flurazepam 
administration as compare to control on cumulative weight gain, gross behavior, open field activity, cage crossing, 
forced swimming, traction and exploratory activity were statistically analyzed by students “t” test. 
Difference between the various groups were considered statistically significant when it is in the acceptance region (p = 
0.05).  
 
5. RESULTS AND DISCUSSION 
Flurazepam binds with BZ1 and BZ2 sites and because of its non selectivity, it  exerts its action of receptors i.e. 
psychomotor  depression,  sedation,  cognition  and  impaired  memory,  sleep  and  blurred  vision.  Zopiclone,  a  non 
benzodiazepines, are  more selective for BZ1 receptors which involves sedation, hypnosis and thus have similar 
hypnotic activity with less propensity of un wanted CNS adverse effects i.e. drowsiness, fatigue and headache. 
The untreated rats move freely in the previously measured field with mean X = 78.3+7.8 (Table-1), while the 
rats treated with zopiclone showed less activity than control with mean 39.8 + 5.69 because of sedative and hypnotic 
effect of the drug. The activity of the animals treated with zopiclone and flurazepam was decreased from control but it 
was more significant with zopiclone. It has also been reported by Denise and Bocca
7 (2003), that zopiclone reduces 
motor activity. This indicates that zopiclone produces reduction in motor activity due to its hypnotic action, and due to 
its action on GABA and NMDA receptors, also zopiclone can produce the effect on nicotinic receptors which might 
also correlate to its effect on reduction in motor activity observed in open field activity. 
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Table-1: Effect of drugs on open field activity of animals 
Groups  Control  Flurazepam treated  Zopiclone treated 
No of models  10  10  10 
Mean (X)  78.3 times  46 times  39.8 times 
Standard deviation (S.D)  +   7.8  +  9.79  +  5.69 
 
Table-2: Effect of drugs on cage crossing activity of animals 
Groups  Control  Flurazepam treated  Zopiclone treated 
No of models  10  10  10 
Mean (X)  76.8  times  39.2 times  36.2 times 
Standard deviation (S.D)  +   4.15  +  6.33  +  8.27 
 
Table-3: Effect of drugs on exploratory activity of animals 
Groups  Control  Flurazepam treated  Zopiclone treated 
No of models  10  10  10 
Mean (X)  52.77 times  27.6 times  27.5 times 
Standard deviation (S.D)  +   7.3  +  4.45  +  6.67 
 
Table-4: Effect of drugs on forced swimming activity of animals 
Groups  Control  Flurazepam treated  Zopiclone treated 
No of models  10  10  10 
Mean (X)  1.60 minutes  1.55 minutes  1.32 minutes 
Standard deviation (S.D)  +   0.37  +  0.49  +  0.31 
 
The controlled rats showed crossing scored with mean X = 76.8 + 4.15 (Table-2) while the rats treated with zopiclone 
showed much decline in scores having mean X = 36.2 + 8.27 may be due to less energy formation as the drug effect 
the cyclooxygenase pathway.  
The cage crossing was decreased by zopiclone and by flurazepam both as compared to control, however the 
effects was more significant for zopiclone, this  decrease is due to effects on GABA receptor that cause calming action 
and leads to decrease locomotory activity. This finding is related to its indication and its mechanism of action .It has 
also been reported by Jeffery .et al.
8 (2001) that zopiclone can affect the locomotory activity. 
The rats treated with flurazepam showed less activity than control with mean X= 39.2 + 6.33, the reduction in the 
locomotory activity by flurazepam was also significant but the reduction was not as marked as was produce by 
zopiclone, the reason for this effect is that flurazepam act as partial agonist also and impairment of motor function is 
not as marked as that for zopiclone. It has also been reported by Ongini .et al.
9 (1981) that flurazepam can cause 
cGMP lowering; this lowering is not the reason for motor impairment i.e. produced by benzodiazepines. This effect 
may be due to increased effect of GABA that decrease the model’s level of anxiety and may produce effect on BZ2 
receptor that affects the motor activity. 
The struggling time shown by the controls were 1.60 + 0.37 minutes (Table-4) then they start swimming, 
while the zopiclone treated rats showed the decrease mean struggling time i.e. 1.32 + 0.31 is observed. This may be 
due to sedation or CNS depression. The struggling time was decreased because zopiclone has anti anxiety activity and 
is metabolites have anxiolytic profile. It is because of this effect that the animal has less struggling time, and animal is 
relaxed and doesn’t show any despair to come out of water tank. It is also reported by Bilhard .et al.
10 (1989) that 
zopiclone can impair hand, eye coordination, which may be a cause also due to which the rats did not show struggling. 
The effect of flurazepam on swimming induced test was that it decrease the time in few animals but was less than that 
of zopiclone, this could also be attributed to a fact that zopiclone act as partial agonist of benzodiazepines leading to 
this effect
11.  
The control rats because of inquisitive nature explore by head dipping with mean X= 52.77 + 7.3(Table-3), 
but the zopiclone treated rats have decreased exploration counts having mean X =27.5 + 6.67 , which might be due to 
calming,  sedative  and  calming  effect  of  zopiclone.  The  activity  of  zopiclone  on  exploratory  activity  was  also 
significant as compare to control and is due to drug anxiolytic profile. This is also reported by Jefferey .et al.
8 (2001), 
that zopiclone and its metabolite has anxiolytic profile. This leads to calming action, slight sedation and a reduction in 
exploratory activity. The anxiolytic profile is also observed for flurazepam but due to sedation effect of zopiclone and 
anxiolytic profile the reduction in exploratory activity is less than that for flurazepam indicating that GABA effects of 
flurazepam can produce more pronounced effects on the cognition and can significantly the exploratory activity.  
The effect of flurazepam on exploratory behaviors of rats is nearly same to that of zopiclone with mean X=27.6 that 
might be due to enhancement of GABA’s effects and sleep induction. It is due to fact that flurazeam has anxiolytic 
activity due to its effect on GABA receptors like other benzodiazepines. This is also in consistent findings of Zhang .et 
al.
11 (1993), according to which there is a decline in spontaneous activity by flurazepam due to decrease in the rate of 
neuronal discharge. Najam et al, 2011 
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All control models shows positive traction and griped the wire, while after treatment with zopiclone most of the rat 
failed to grip the wire that may be due to sedation and hypnosis induction. 
Confusion,  drowsiness,  sedation,  less  respond  to  reflexes  and  over  all  decrease  in  mental  activity  was  observed 
because of sedative and depressive effect, while urination, defecation and salivation is normal. 
The number of gross behavioral effects were observed during the present work includes decrease locomotory activity, 
zopiclone significantly reduced locomotory activity which is also observed in our study. From the facts that zopiclone 
inhibits locomotor activity in rats, and inhibits brain dopamine and 5 HT turn over, the mechanism of action of 
zopiclone in brain neurons is similar to that of benzodiazepine derivatives. Our results of the present research work are 
in accordance with the research of Liu .et al.
13 (1985).  
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